Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Goff

Showing results (451-460 of 527) with videos related to

Pageof 53
Sort By:
Journal of the American Heart Association|September 23, 2015
Can Antihypertensive Treatment Restore the Risk of Cardiovascular Disease to Ideal Levels?: The Coronary Artery Risk Development in Young Adults (CARDIA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)Kiang Liu, Laura A Colangelo, Martha L Daviglus, et al.
Journal of the American Heart Association|March 29, 2021
Longitudinal Associations of Fitness and Obesity in Young Adulthood With Right Ventricular Function and Pulmonary Artery Systolic Pressure in Middle Age: The CARDIA StudyKershaw V Patel, Mark Metzinger, Bryan Park, et al.
Schizophrenia Research|September 9, 2008
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia studyGail L Daumit, Donald C Goff, Jonathan M Meyer, et al.
Circulation|July 27, 2011
Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart AssociationWilliam S Weintraub, Stephen R Daniels, Lora E Burke, et al.
Archives of General Psychiatry|January 5, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysisDavid C Henderson, Enrico Cagliero, Paul M Copeland, et al.
Schizophrenia Research|March 15, 2020
Air pollution and hippocampal atrophy in first episode schizophreniaMichelle A Worthington, Eva Petkova, Oliver Freudenreich, et al.
Schizophrenia Research|February 3, 2019
Citalopram in first episode schizophrenia: The DECIFER trialDonald C Goff, Oliver Freudenreich, Corrine Cather, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2008
MTHFR 677C --> T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> MetJoshua L Roffman, Randy L Gollub, Vince D Calhoun, et al.
Diabetes Care|April 30, 2010
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trialMatthew C Riddle, Walter T Ambrosius, David J Brillon, et al.
American Journal of Preventive Medicine|May 20, 2018
Racial Disparities in Cardiovascular Health Behaviors: The Coronary Artery Risk Development in Young Adults StudyKara M Whitaker, David R Jacobs, Kiarri N Kershaw, et al.
Pageof 53

Showing results (451-460 of 527) with videos related to

Sort By:
Pageof 53
Journal of the American Heart Association|September 23, 2015
Can Antihypertensive Treatment Restore the Risk of Cardiovascular Disease to Ideal Levels?: The Coronary Artery Risk Development in Young Adults (CARDIA) Study and the Multi-Ethnic Study of Atherosclerosis (MESA)Kiang Liu, Laura A Colangelo, Martha L Daviglus, et al.
Journal of the American Heart Association|March 29, 2021
Longitudinal Associations of Fitness and Obesity in Young Adulthood With Right Ventricular Function and Pulmonary Artery Systolic Pressure in Middle Age: The CARDIA StudyKershaw V Patel, Mark Metzinger, Bryan Park, et al.
Schizophrenia Research|September 9, 2008
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia studyGail L Daumit, Donald C Goff, Jonathan M Meyer, et al.
Circulation|July 27, 2011
Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart AssociationWilliam S Weintraub, Stephen R Daniels, Lora E Burke, et al.
Archives of General Psychiatry|January 5, 2005
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysisDavid C Henderson, Enrico Cagliero, Paul M Copeland, et al.
Schizophrenia Research|March 15, 2020
Air pollution and hippocampal atrophy in first episode schizophreniaMichelle A Worthington, Eva Petkova, Oliver Freudenreich, et al.
Schizophrenia Research|February 3, 2019
Citalopram in first episode schizophrenia: The DECIFER trialDonald C Goff, Oliver Freudenreich, Corrine Cather, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2008
MTHFR 677C --> T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val --> MetJoshua L Roffman, Randy L Gollub, Vince D Calhoun, et al.
Diabetes Care|April 30, 2010
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trialMatthew C Riddle, Walter T Ambrosius, David J Brillon, et al.
American Journal of Preventive Medicine|May 20, 2018
Racial Disparities in Cardiovascular Health Behaviors: The Coronary Artery Risk Development in Young Adults StudyKara M Whitaker, David R Jacobs, Kiarri N Kershaw, et al.
Pageof 53